Clinical Trial Update: Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 intrathecal gene therapy trial for SLC13A5 Citrate Transporter Disorder, currently NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Slc13a5 Citrate Transporter Disorder

Drugs mentioned

• Undisclosed intrathecal gene therapy

Snippet

Sponsor: TESS Research Foundation | Conditions: SLC13A5 Citrate Transporter Disorder | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING